Drs. Fizazi, Wallis on Updated Data from TALAPRO-2

By Karim Fizazi, MD, PhD, Christopher Wallis, MD, PhD, FRCSC - Last Updated: August 1, 2023

Karim Fizazi, MD, PhD, Gustave Roussy Cancer Institute, and Christopher Wallis, MD, PhD, University of Toronto, detail the latest updates regarding the phase 3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line treatment for patients with mCRPC harboring homologous recombination repair gene alterations.

The updated results of TALAPRO-2 has since led to the FDA approval of talazoparib in combination with enzalutamide for HRR-Mutated mCRPC.

View more ASCO 2023 videos.